Compare Hormel Foods Corp (HRL) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Zimmer Biomet Holdings Inc — how do they compare? Hormel Foods Corp trades at $25.06 (market cap $13.91B), while Zimmer Biomet Holdings Inc trades at $89.6 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and Hormel Foods Corp pays the higher dividend (4.63%). Which is the better fit depends on your goals.
| HRL | ZBH | |
|---|---|---|
Market Cap | $13.91B | $17.36B |
Sector | Consumer Staples | Health |
52-Week High | $29.52 | $107.71 |
52-Week Low | $19.74 | $79.58 |
Enterprise Value | $15.91B | $24.40B |
Dividend Yield | 4.63% | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $25.31, down 0.33% on the day, with a bullish technical outlook and consistent earnings beats. The stock shows a P/E of 29.87 and net income margin of 3.82%, supported by a recent dividend of $0.29. Revenue for 2025 was $12.11B, though net income declined to $478.20M. Analysts maintain a mixed consensus with a $26.33 price target, while the company focuses on portfolio streamlining, such as the sale of its Ceratti business in Brazil (PRNewsWire, 2026-06-29).
HRL offers a stable dividend yield and is near multi-year lows, presenting a value opportunity amid sector weakness. Risks include margin pressure from input costs and competitive threats in the consumer staples space. Institutional sentiment is cautious with 57% hold ratings, but technical indicators suggest potential upside if earnings momentum continues.
Zimmer Biomet (ZBH) trades at $89.74, down 1.51% on the day, with a bullish technical signal from moving averages and a consensus price target of $97.67. The company reported revenue of $8.23B in 2025, with net income of $705.10M and a net margin of 8.56%. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase program, while Q2 2026 earnings are anticipated on August 5, 2026.
ZBH presents a mixed outlook with strong profitability margins and recent earnings beats offset by declining net income margins and rising debt levels. The stock offers potential upside to analyst targets but faces execution risks in competitive medical markets and macroeconomic pressures on healthcare spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
